CN1054376C - 取代的1h-咪唑 - Google Patents

取代的1h-咪唑 Download PDF

Info

Publication number
CN1054376C
CN1054376C CN95120834A CN95120834A CN1054376C CN 1054376 C CN1054376 C CN 1054376C CN 95120834 A CN95120834 A CN 95120834A CN 95120834 A CN95120834 A CN 95120834A CN 1054376 C CN1054376 C CN 1054376C
Authority
CN
China
Prior art keywords
imidazoles
compound
tetrahydrochysene
naphthyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN95120834A
Other languages
English (en)
Chinese (zh)
Other versions
CN1133837A (zh
Inventor
J·P·吉尔斯
G·莫特
E·迪佛尔丁格
J·P·海尼查特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of CN1133837A publication Critical patent/CN1133837A/zh
Application granted granted Critical
Publication of CN1054376C publication Critical patent/CN1054376C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN95120834A 1994-12-14 1995-12-12 取代的1h-咪唑 Expired - Fee Related CN1054376C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9425211.1 1994-12-14
GBGB9425211.1A GB9425211D0 (en) 1994-12-14 1994-12-14 Substituted 1H-imidazoles

Publications (2)

Publication Number Publication Date
CN1133837A CN1133837A (zh) 1996-10-23
CN1054376C true CN1054376C (zh) 2000-07-12

Family

ID=10765918

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95120834A Expired - Fee Related CN1054376C (zh) 1994-12-14 1995-12-12 取代的1h-咪唑

Country Status (26)

Country Link
US (1) US5658938A (enExample)
EP (1) EP0717037A1 (enExample)
JP (1) JPH08208622A (enExample)
KR (1) KR960022474A (enExample)
CN (1) CN1054376C (enExample)
AR (1) AR002257A1 (enExample)
AU (1) AU693614B2 (enExample)
BG (1) BG63043B1 (enExample)
BR (1) BR9505815A (enExample)
CA (1) CA2165133A1 (enExample)
CZ (1) CZ327195A3 (enExample)
EE (1) EE9500064A (enExample)
FI (1) FI955927A7 (enExample)
GB (1) GB9425211D0 (enExample)
HU (1) HUT73980A (enExample)
IL (1) IL116325A (enExample)
IS (1) IS4311A (enExample)
MX (1) MX9505063A (enExample)
NO (1) NO305316B1 (enExample)
NZ (1) NZ280646A (enExample)
PL (1) PL311736A1 (enExample)
RO (1) RO113346B1 (enExample)
RU (1) RU2156239C2 (enExample)
SK (1) SK155095A3 (enExample)
TW (1) TW303362B (enExample)
ZA (1) ZA9510554B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104603129A (zh) * 2012-09-17 2015-05-06 霍夫曼-拉罗奇有限公司 三唑甲酰胺衍生物

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
ZA981080B (en) * 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
US6503935B1 (en) * 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
US20030073850A1 (en) * 1998-08-07 2003-04-17 Altenbach Robert J. 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
AU2001258469B2 (en) 2000-05-08 2005-04-14 Orion Corporation New polycyclic indanylimidazoles with alpha2 adrenergic activity
TW200930291A (en) * 2002-04-29 2009-07-16 Bayer Cropscience Ag Pesticidal heterocycles
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
FI20022007A0 (fi) * 2002-11-08 2002-11-08 Juvantia Pharma Ltd Oy Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi
FI20022159A0 (fi) * 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä
KR20080090545A (ko) * 2006-01-27 2008-10-08 에프. 호프만-라 로슈 아게 Ｃｎｓ 장애 치료용 2-이미다졸의 용도
MX2009003801A (es) * 2006-10-19 2009-04-22 Hoffmann La Roche Aminometil-4-imidazoles.
BRPI0718059A2 (pt) * 2006-10-19 2013-11-05 Holffmann La Roche Ag F Aminometil-2-imidazóis com afinidade com os receptores amina-associado traço
BRPI0718054A2 (pt) * 2006-11-02 2013-11-05 Hoffmann La Roche 2-imidazóis substituídos como moduladores de receptores associados à traços de aminas
AU2007321376A1 (en) * 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
WO2008071574A1 (en) * 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (taar)
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
CA2675221C (en) * 2007-02-02 2016-02-23 F. Hoffmann-La Roche Ag Novel 2-aminooxazolines as taar1 ligands
MX2009008776A (es) * 2007-02-13 2009-08-25 Schering Corp Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
BRPI0807961A2 (pt) * 2007-02-13 2017-05-16 Pharmacopeia Llc agonista de alfa2c adrenorreceptor funcionalmente seletivos.
WO2008100459A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
MX2009008465A (es) * 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
CA2691082A1 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
BRPI0812833A2 (pt) * 2007-07-03 2014-12-09 Hoffmann La Roche 4-imidazolinas e seu uso como antidepressivos
KR101133862B1 (ko) * 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Ｔａａｒ 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
CN101765425A (zh) * 2007-08-02 2010-06-30 弗·哈夫曼-拉罗切有限公司 苯甲酰胺衍生物用于治疗cns障碍的用途
CA2695331A1 (en) * 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
CL2008003553A1 (es) * 2007-12-05 2009-11-27 Grindeks Jsc Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso
US8383818B2 (en) 2008-02-21 2013-02-26 Merck Sharp & Dohme Corp. Functionally selective alpha2C adrenoreceptor agonists
US8242153B2 (en) * 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
ES2556633T3 (es) * 2008-07-24 2016-01-19 F. Hoffmann-La Roche Ag Derivados de 4,5-dihidro-oxazol-2-ilo
WO2010017120A1 (en) * 2008-08-04 2010-02-11 Schering Corporation Cyclopropylchromene derivatives as modulators of the alpha-2c receptor
EP2356106A1 (en) 2008-10-07 2011-08-17 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
US20100311798A1 (en) * 2009-06-05 2010-12-09 Decoret Guillaume 2-aminooxazolines as taar1 ligands
US8354441B2 (en) * 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8673950B2 (en) 2010-11-02 2014-03-18 Hoffmann-Laroche Inc. Dihydrooxazol-2-amine derivatives
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
BR112014015832A8 (pt) 2012-01-12 2017-07-04 Hoffmann La Roche derivados heterocíclicos como receptores associados com aminas vistigiais (taars)
HRP20171981T1 (hr) 2012-09-14 2018-02-09 F. Hoffmann - La Roche Ag Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti
WO2015165085A1 (en) 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
CN106470994B (zh) 2014-08-27 2019-09-24 豪夫迈·罗氏有限公司 用于治疗cns疾病的取代的吡嗪并[2,1-a]异喹啉衍生物
EP3186224B1 (en) 2014-08-27 2021-04-21 F. Hoffmann-La Roche AG Substituted azetidine derivatives as taar ligands
RS60825B1 (sr) 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a
PL3429352T3 (pl) * 2016-03-17 2022-08-22 Fmc Corporation Sposób konwersji enancjomeru-S do jego postaci racemicznej
CN116496261B (zh) * 2023-03-09 2025-06-27 中国人民解放军军事科学院军事医学研究院 4-(1h)-咪唑类衍生物及其医药用途
CN118684628B (zh) * 2024-05-20 2025-06-17 中国人民解放军军事科学院军事医学研究院 取代二氢茚基咪唑类化合物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269599A2 (fr) * 1986-11-04 1988-06-01 U C B, S.A. 1H-Imidazoles substitués

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6048972A (ja) * 1983-08-25 1985-03-16 Dai Ichi Seiyaku Co Ltd テトラヒドロナフタレン誘導体
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5151526A (en) * 1990-10-11 1992-09-29 The United States Of America As Represented By The Secretary Of The Army 4-[1-(1-naphthalenyl)ethyl]-1H-imidazole, method of making and use as an anesthetic
JPH04210680A (ja) * 1990-12-01 1992-07-31 Nissan Chem Ind Ltd イミダゾール誘導体および植物生長調節剤
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269599A2 (fr) * 1986-11-04 1988-06-01 U C B, S.A. 1H-Imidazoles substitués

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104603129A (zh) * 2012-09-17 2015-05-06 霍夫曼-拉罗奇有限公司 三唑甲酰胺衍生物

Also Published As

Publication number Publication date
KR960022474A (ko) 1996-07-18
IL116325A (en) 1999-10-28
IS4311A (is) 1996-06-15
EP0717037A1 (fr) 1996-06-19
FI955927L (fi) 1996-06-15
IL116325A0 (en) 1996-03-31
BR9505815A (pt) 1998-01-06
RU2156239C2 (ru) 2000-09-20
EE9500064A (et) 1996-06-17
CA2165133A1 (en) 1996-06-15
SK155095A3 (en) 1997-02-05
HUT73980A (en) 1996-10-28
TW303362B (enExample) 1997-04-21
FI955927A7 (fi) 1996-06-15
ZA9510554B (en) 1996-06-13
BG63043B1 (bg) 2001-02-28
PL311736A1 (en) 1996-06-24
AU693614B2 (en) 1998-07-02
AR002257A1 (es) 1998-03-11
GB9425211D0 (en) 1995-02-15
RO113346B1 (ro) 1998-06-30
BG100208A (bg) 1996-07-31
CZ327195A3 (en) 1996-07-17
FI955927A0 (fi) 1995-12-11
US5658938A (en) 1997-08-19
NZ280646A (en) 1996-08-27
AU4036895A (en) 1996-06-20
JPH08208622A (ja) 1996-08-13
NO955034D0 (no) 1995-12-12
CN1133837A (zh) 1996-10-23
NO305316B1 (no) 1999-05-10
NO955034L (no) 1996-06-17
HU9503549D0 (en) 1996-02-28
MX9505063A (es) 1997-01-31

Similar Documents

Publication Publication Date Title
CN1133837A (zh) 取代的1h-咪唑
CN1056373C (zh) 含氮杂环类化合物的氟代烷氧基苄氨基衍生物的制备方法
CN1036920C (zh) 含杂环碳酸衍生物
CN1036652C (zh) 碱式季酰胺，其制备方法及其药物组合物
CN1203070C (zh) 凝血酶受体拮抗药
CN1053190C (zh) 新的喹喔啉二酮衍生物、其制备方法和作为药物的应用
CN87107875A (zh) 四氢化萘衍生物
CN1214339A (zh) 吡唑衍生物、其制备方法和在药物中的应用
CN1047080A (zh) 嘧啶衍生物
CN1042133C (zh) N－取代的氮杂双环庚烷衍生物及其用途
CN1009092B (zh) 吡啶酮衍生物的制备方法
CN1033995A (zh) 抑制芳香酶的4(5)-咪唑
CN87101830A (zh) 二氯苯胺衍生物
CN1018614B (zh) 制备含n-杂环基-4-哌啶胺类的抗组胺组合物的方法
CN1198741A (zh) 具有α2受体亲合活性的咪唑衍生物
EP0377528B1 (fr) Pipéridines, procédés de préparation et médicaments les contenant
CN1535148A (zh) 调节钠通道的咪唑衍生物
CN1468224A (zh) 用作α-2拮抗剂的喹啉衍生物
CN1023219C (zh) 取代的咪唑衍生物的制备方法
CN1166833A (zh) 嘧啶基吡唑衍生物
CN1017901B (zh) 抗精神病药稠环吡啶基哌嗪衍生物的制备方法
CN87104641A (zh) 4-(芳酰氨基)哌啶丁酰氨衍生物
CN1012364B (zh) 治疗老年精神病的环酰胺和酰亚胺的二氮杂苯基哌啶衍生物的制备方法
CN1257864A (zh) 新的咪唑啉化合物、其制备方法和含有它们的药物组合物
CN86102329A (zh) 氨基酮的新的衍生物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee